{
    "nodes": [
        {
            "label": "Company",
            "name": "삼성바이오로직스",
            "properties": {
                "industry": "제약바이오",
                "name": "삼성바이오로직스"
            }
        },
        {
            "label": "Company",
            "name": "Celltrion",
            "properties": {
                "name": "Celltrion",
                "country": "South Korea",
                "industry": "Biotechnology",
                "annual_revenue": 5000000000
            }
        },
        {
            "label": "Product",
            "name": "케이캡",
            "properties": {
                "name": "케이캡",
                "category": "위식도역류질환 치료제"
            }
        }
    ],
    "relations": [
        {
            "start_node": "삼성바이오로직스",
            "relationship": "USES_TECHNOLOGY",
            "end_node": "Celltrion",
            "properties": {
                "description": "Both companies are involved in biosimilars production, which contributed to their revenue."
            }
        },
        {
            "start_node": "삼성바이오로직스",
            "relationship": "PRODUCES",
            "end_node": "케이캡",
            "properties": {
                "description": "Samsung Biologics' increase in earnings attributed to biosimilars."
            }
        }
    ]
}